Skip to Content
COVID-19 Response and Update

We make healthy possible

 
CREXONT®

FDA approves IPX203 for treatment of Parkinson’s Disease in adults. To be launched as CREXONT® (carbidopa and levodopa) extended-release capsules.

The most common adverse reactions are nausea and anxiety. For full prescribing information, see our product labeling.

Product Labeling(Opens in a new window) Product Website(Opens in a new window)

 

Our products

Our broad portfolio of approximately 280+ generic and specialty pharmaceuticals is the foundation from which we make healthy possible. And we expanded our portfolios to institutions, in biosimilars and across select international markets.

Generics Products Specialty Products Biosciences Products Expanded Access Policy

 
  • Touching lives

  • Our family works for yours.
    See how we're making healthy possible.
    Read More >

 

Press releases

We’re committed to delivering value. Learn more about the meaningful difference we’re making for people and healthcare.

 

See other news
Our Culture

Our culture

Our culture is driven by actions that inspire us to Rise, Lead and Succeed – for patients and their families.

 

See our culture in action

Join our family

Apply your passion and talents to help us touch more lives.

 

See our opportunities